PharmTech Drug Digest 11.20
News|Articles|June 27, 2017

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-07-05-2017
  • Volume 12
  • Issue 7

Itzhak Krinsky Joins Halo Pharma Board of Directors

Krinsky joined the board of directors at Halo after working for Teva Pharmaceuticals for 12 years.

On June 27, 2017, Halo Pharma announced the appointment of Itzhak Krinsky, PhD, to its board of directors. Krinsky has experience in the pharmaceutical industry, investment banking, and an academic career in finance and business economics. Prior to joining Halo, Krinsky worked for Teva Pharmaceuticals for 12 years. He retired from Teva earlier in 2017. During his tenure at Teva, Krinsky served as executive vice-president of Corporate Business Development, a member of the Teva executive committee, chairman of Teva Japan, chairman of Teva South Korea, and head of Business Development Asia Pacific.

Prior to joining Teva, he held various senior positions in investment banks in New York City including with Bankers Trust, Deutsche Bank, and the Silverfern Group, Inc. Krinsky also served as a professor of Finance and Business Economics at the Michael G. DeGroote School of Business, McMaster University, Ontario, Canada. He has published more than 80 articles in peer-reviewed academic journals.

Source: Halo Pharma


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.